Literature DB >> 31858126

Testosterone Increases the Expression and Phosphorylation of AMP Kinase α in Men With Hypogonadism and Type 2 Diabetes.

Husam Ghanim1, Sandeep Dhindsa1,2, Manav Batra1, Kelly Green1, Sanaa Abuaysheh1, Nitesh D Kuhadiya1, Antoine Makdissi1, Ajay Chaudhuri1, Sartaj Sandhu1, Paresh Dandona1.   

Abstract

CONTEXT: Adenosine 5'-monophosphate-activated protein kinase-α (AMPKα) is a mediator of exercise-induced glucose uptake in skeletal muscle.
OBJECTIVE: We evaluated whether AMPKα expression and phosphorylation are reduced in skeletal muscle and adipose tissue of patients with hypogonadotropic hypogonadism (HH), and whether testosterone replacement therapy results in restoration of the expression and phosphorylation of AMPKα.
DESIGN: This is a secondary analysis of a previously completed trial that showed an insulin-sensitizing effect of testosterone therapy in men with type 2 diabetes and HH.
SETTING: Clinical research center at university. PATIENTS: Thirty-two men with HH and 32 eugonadal men were compared at baseline.
INTERVENTIONS: Men with HH were treated with intramuscular injections of testosterone or placebo every 2 weeks for 22 weeks. Quadriceps muscle biopsies and subcutaneous abdominal fat biopsies were obtained before and after 4-hour euglycemic hyperinsulinemic clamp, prior to and after testosterone or placebo therapy. OUTCOME MEASURES AND
RESULTS: mRNA expression of AMPKα in hypogonadal men was lower by 37% in adipose tissue and 29% in skeletal muscle, respectively, compared with levels in eugonadal men, while phosphorylated AMPKα was lower by 22% and 28%, respectively. Following testosterone replacement, the expression of AMPKα did not alter in the fasting state but increased markedly by 41% and 46% in adipose tissue and muscle, respectively, after the clamp. In contrast, phosphorylated AMPKα increased by 69% in muscle after testosterone therapy but did not change following the clamp.
CONCLUSIONS: Testosterone modulates the expression of AMPKα and phosphorylated AMPKα. These effects may contribute to the improved insulin sensitivity following testosterone therapy. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  AMP kinase; AMPK; adipose; hypogonadism; muscle; testosterone

Year:  2020        PMID: 31858126      PMCID: PMC7077952          DOI: 10.1210/clinem/dgz288

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Effect of Testosterone on FGF2, MRF4, and Myostatin in Hypogonadotropic Hypogonadism: Relevance to Muscle Growth.

Authors:  Husam Ghanim; Sandeep Dhindsa; Manav Batra; Kelly Green; Sanaa Abuaysheh; Nitesh D Kuhadiya; Antoine Makdissi; Ajay Chaudhuri; Paresh Dandona
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

2.  Leucine or carbohydrate supplementation reduces AMPK and eEF2 phosphorylation and extends postprandial muscle protein synthesis in rats.

Authors:  Gabriel J Wilson; Donald K Layman; Christopher J Moulton; Layne E Norton; Tracy G Anthony; Christopher G Proud; S Indu Rupassara; Peter J Garlick
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-09-13       Impact factor: 4.310

Review 3.  AMPK as a Therapeutic Target for Treating Metabolic Diseases.

Authors:  Emily A Day; Rebecca J Ford; Gregory R Steinberg
Journal:  Trends Endocrinol Metab       Date:  2017-06-21       Impact factor: 12.015

Review 4.  AMPK: a nutrient and energy sensor that maintains energy homeostasis.

Authors:  D Grahame Hardie; Fiona A Ross; Simon A Hawley
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-22       Impact factor: 94.444

5.  Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes.

Authors:  Sandeep Dhindsa; Husam Ghanim; Manav Batra; Nitesh D Kuhadiya; Sanaa Abuaysheh; Sartaj Sandhu; Kelly Green; Antoine Makdissi; Jeanne Hejna; Ajay Chaudhuri; Mark Punyanitya; Paresh Dandona
Journal:  Diabetes Care       Date:  2015-11-29       Impact factor: 19.112

6.  AMP-activated protein kinase (AMPK)α2 plays a role in determining the cellular fate of glucose in insulin-resistant mouse skeletal muscle.

Authors:  R S Lee-Young; J S Bonner; W H Mayes; I Iwueke; B A Barrick; C M Hasenour; L Kang; D H Wasserman
Journal:  Diabetologia       Date:  2012-12-08       Impact factor: 10.122

7.  Tumor necrosis factor alpha inhibits signaling from the insulin receptor.

Authors:  G S Hotamisligil; D L Murray; L N Choy; B M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

8.  Sex steroids and all-cause and cause-specific mortality in men.

Authors:  Andre B Araujo; Varant Kupelian; Stephanie T Page; David J Handelsman; William J Bremner; John B McKinlay
Journal:  Arch Intern Med       Date:  2007-06-25

9.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

Authors:  Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Aage Vølund; Jan A Ehses; Burkhardt Seifert; Thomas Mandrup-Poulsen; Marc Y Donath
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

Review 10.  Hypogonadotropic Hypogonadism in Men With Diabesity.

Authors:  Sandeep Dhindsa; Husam Ghanim; Manav Batra; Paresh Dandona
Journal:  Diabetes Care       Date:  2018-07       Impact factor: 19.112

View more
  7 in total

1.  Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes.

Authors:  Georgia Colleluori; Lina Aguirre; Nicola Napoli; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 6.134

Review 2.  Androgen-Regulated Cardiac Metabolism in Aging Men.

Authors:  Genaro Barrientos; Paola Llanos; Carla Basualto-Alarcón; Manuel Estrada
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-15       Impact factor: 5.555

3.  Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study.

Authors:  Karim Sultan Haider; Ahmad Haider; Farid Saad; Gheorghe Doros; Markolf Hanefeld; Sandeep Dhindsa; Paresh Dandona; Abdulmaged Traish
Journal:  Diabetes Obes Metab       Date:  2020-07-15       Impact factor: 6.577

Review 4.  Mitochondria in Sex Hormone-Induced Disorder of Energy Metabolism in Males and Females.

Authors:  Lijun Yin; Man Luo; Ru Wang; Jianping Ye; Xiaohui Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-20       Impact factor: 5.555

5.  Effect of Metformin on Testosterone Levels in Male Patients With Type 2 Diabetes Mellitus Treated With Insulin.

Authors:  Tingting Cai; Yun Hu; Bo Ding; Rengna Yan; Bingli Liu; Ling Cai; Ting Jing; Lanlan Jiang; Xiaojing Xie; Yuming Wang; Huiying Wang; Yunting Zhou; Ke He; Lan Xu; Liang Chen; Cheng Cheng; Jianhua Ma
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-24       Impact factor: 5.555

6.  The relationship between sex hormones and glycated hemoglobin in a non-diabetic middle-aged and elderly population.

Authors:  Yiting Xu; Weijie Cao; Yun Shen; Junling Tang; Yufei Wang; Xiaojing Ma; Yuqian Bao
Journal:  BMC Endocr Disord       Date:  2022-04-05       Impact factor: 2.763

7.  Testosterone ameliorates age-related brain mitochondrial dysfunction.

Authors:  Wensheng Yan; Tianyun Zhang; Yunxiao Kang; Guoliang Zhang; Xiaoming Ji; Xu Feng; Geming Shi
Journal:  Aging (Albany NY)       Date:  2021-06-17       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.